FDA Form 483 Response

FDA FORM 483 INSPECTION OBSERVATIONS RESPONSE

RESPONSE COVER LETTER

Date: [__/__/____]

Via Electronic Submission and/or Certified Mail

Food and Drug Administration
[________________________________]
[________________________________]
[________________________________]

Attn: [________________________________], Investigator

Re: Response to FDA Form 483 Observations
Inspection Dates: [__/__/____] to [__/__/____]
Firm Name: [________________________________]
FEI Number: [________________________________]
Establishment Type: [________________________________]

Dear [________________________________]:

This letter constitutes [________________________________] ("Company") formal response to the FDA Form 483 Inspectional Observations issued on [__/__/____] following the inspection conducted at our facility located at [________________________________].

We appreciate the professionalism of the FDA investigators during the inspection and take the observations seriously. We are committed to operating in full compliance with FDA regulations and have taken immediate steps to address each observation.

SECTION 1: COMPANY INFORMATION

1.1 Facility Information

1.2 Inspection Summary

SECTION 2: EXECUTIVE SUMMARY OF CORRECTIVE ACTIONS

2.1 Summary Table

2.2 Overall Compliance Commitment

[________________________________]

SECTION 3: DETAILED RESPONSE TO OBSERVATIONS

OBSERVATION 1

FDA Observation (verbatim):

[________________________________]

Regulatory Reference: [________________________________]

3.1.1 Root Cause Analysis

Investigation Method Used:
☐ 5 Whys Analysis
☐ Fishbone (Ishikawa) Diagram
☐ Failure Mode Effects Analysis (FMEA)
☐ Fault Tree Analysis
☐ Other: [________________________________]

Root Cause Determination:

[________________________________]

Contributing Factors:

☐ Procedure/SOP deficiency
☐ Training inadequacy
☐ Equipment/facility issue
☐ Human error
☐ Supplier/material issue
☐ Documentation gap
☐ Other: [________________________________]

3.1.2 Immediate Corrections (Completed)

3.1.3 Corrective Actions (CAPA)

3.1.4 Preventive Actions

[________________________________]

3.1.5 Effectiveness Verification Plan

3.1.6 Documentation Attached for Observation 1

☐ Revised SOP: [________________________________]
☐ Training Records
☐ Batch/Production Records
☐ Test Results
☐ Photographs
☐ Root Cause Analysis Documentation
☐ Other: [________________________________]

OBSERVATION 2

FDA Observation (verbatim):

[________________________________]

Regulatory Reference: [________________________________]

3.2.1 Root Cause Analysis

Investigation Method Used:
☐ 5 Whys Analysis
☐ Fishbone (Ishikawa) Diagram
☐ Failure Mode Effects Analysis (FMEA)
☐ Fault Tree Analysis
☐ Other: [________________________________]

Root Cause Determination:

[________________________________]

Contributing Factors:

☐ Procedure/SOP deficiency
☐ Training inadequacy
☐ Equipment/facility issue
☐ Human error
☐ Supplier/material issue
☐ Documentation gap
☐ Other: [________________________________]

3.2.2 Immediate Corrections (Completed)

3.2.3 Corrective Actions (CAPA)

3.2.4 Preventive Actions

[________________________________]

3.2.5 Effectiveness Verification Plan

3.2.6 Documentation Attached for Observation 2

☐ Revised SOP: [________________________________]
☐ Training Records
☐ Batch/Production Records
☐ Test Results
☐ Photographs
☐ Root Cause Analysis Documentation
☐ Other: [________________________________]

OBSERVATION 3

FDA Observation (verbatim):

[________________________________]

Regulatory Reference: [________________________________]

3.3.1 Root Cause Analysis

Root Cause Determination:

[________________________________]

3.3.2 Immediate Corrections (Completed)

3.3.3 Corrective and Preventive Actions (CAPA)

3.3.4 Documentation Attached for Observation 3

☐ Revised SOP
☐ Training Records
☐ Other: [________________________________]

SECTION 4: SYSTEMIC IMPROVEMENTS

4.1 Quality System Enhancements

☐ Quality Manual revised
☐ CAPA procedure updated
☐ Internal audit program strengthened
☐ Management review process enhanced
☐ Document control procedures improved
☐ Training program expanded
☐ Supplier qualification program updated
☐ Equipment maintenance program revised

Details:

[________________________________]

4.2 Training Summary

4.3 Management Commitment

[________________________________]

SECTION 5: IMPLEMENTATION TIMELINE

5.1 Gantt Chart / Timeline Summary

5.2 Progress Reporting Commitment

☐ We commit to providing FDA with progress updates at the following intervals:
[________________________________]

SECTION 6: PRODUCT IMPACT ASSESSMENT

6.1 Product Evaluation

☐ No products were impacted by the observations
☐ Products were evaluated - no safety concern identified
☐ Products were quarantined pending investigation
☐ Products were voluntarily recalled (see Section 6.2)

Product Impact Details:

[________________________________]

6.2 Recall Information (if applicable)

SECTION 7: CONTACT INFORMATION

Primary Contact:

Name: [________________________________]

Title: [________________________________]

Phone: [________________________________]

Email: [________________________________]

Alternate Contact:

Name: [________________________________]

Title: [________________________________]

Phone: [________________________________]

Email: [________________________________]

SECTION 8: CERTIFICATION

I certify that the information provided in this response is accurate and complete. The Company is fully committed to compliance with FDA regulations and implementing the corrective actions described herein.

Signature: ________________________________________

Printed Name: [________________________________]

Title: [________________________________]

Date: [__/__/____]

ATTACHMENTS INDEX

IMPORTANT REGULATORY NOTES

Response Timeline

• 15 Business Days: FDA expects a response within 15 business days of Form 483 issuance
• Extensions may be requested if the Form 483 is extensive
• A good-faith response can help avoid escalation to a Warning Letter

Form 483 vs. Warning Letter

• Form 483 documents observations; it is NOT a final FDA determination
• Inadequate response may result in Warning Letter issuance
• Form 483 observations are public record after the inspection closes

Dispute Resolution

• You have 30 calendar days to use FDA's formal dispute resolution process
• Refer to: "Guidance for Industry - Formal Dispute Resolution: Scientific and Technical Issues Related to Pharmaceutical CGMP"

Best Practices

• Respond to EVERY observation individually
• Include specific timelines and responsible parties
• Provide objective evidence of completed corrections
• Be honest about items still in progress
• Avoid defensive language; focus on corrective actions

SOURCES AND REFERENCES

• FDA Form 483 Frequently Asked Questions
• FDA Regulatory Procedures Manual Chapter 5
• 21 CFR Part 117 (Food), Part 111 (Supplements), Part 211 (Drugs)
• FDA Guidance: Formal Dispute Resolution

This template is provided for informational purposes only. Each Form 483 response must be tailored to the specific observations and circumstances involved. Legal counsel experienced in FDA regulatory matters should review any response before submission.